ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
A new therapy paradigm for prostate cancer founded on clinical observations.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.Clinical genitourinary cancer · 2021Trial
- Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.European urology · 2015Trial
- Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers.The Prostate · 2013Trial
- Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Trial
- Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.Frontiers in pharmacology · 2024Review
- Prediction of disease progression indicators in prostate cancer patients receiving HDR-brachytherapy using Raman spectroscopy and semi-supervised learning: a pilot study.Scientific reports · 2022Article
- IL-8 Secreted from M2 Macrophages Promoted Prostate Tumorigenesis via STAT3/MALAT1 Pathway.International journal of molecular sciences · 2018Article
- Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.Yonsei medical journal · 2015Article
- Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.The Journal of biological chemistry · 2015Article
- Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.The Prostate · 2013Article
- Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.Cancer discovery · 2013Review
- Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.The Journal of biological chemistry · 2012Article
- The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.Cancer management and research · 2012Article
- Novel therapies for metastatic castrate-resistant prostate cancer.Journal of the National Cancer Institute · 2011Review
- Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer.Oncogene · 2011Article
- Abiraterone acetate.Nature reviews. Drug discovery · 2011Article
- Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment.NMR in biomedicine · 2011Article
- Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling.Histopathology · 2011Article
- Steps in prostate cancer progression that lead to bone metastasis.International journal of cancer · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Efficacy equivalent to that reported in other common adult solid tumors considered to be chemotherapy-sensitive has been reported with Docetaxel in patients with castrate-resistant prostate cancer. However, in contrast to other cancers, the expected increase in efficacy with the use of chemotherapy in earlier disease states has not been reported to date in prostate cancer. On the basis of these observations, we speculated that the therapy development paradigm used successfully in other cancers may not apply to the majority of prostate cancers. Several lines of supporting clinical and experimental observations implicate the tumor microenvironment in prostate carcinogenesis and resistance to therapy. We conclude that a foundation to guide the development of therapy for prostate cancer is required. The therapy paradigm we propose accounts for the central role of the tumor microenvironment in bone and, if correct, will lead to microenvironment-targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.